Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07090330 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

Study acronym: EVERLAST-A
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Apr 2026 to Mar 25, 2026 Site details revised at 2 of 26 sitesv6 Show 1 more changeShow less
    • Site details revised at 2 of 26 sites
  2. Trial status: Recruiting to Active, Not Recruiting Primary completion date: Sep 2026 to Apr 2026 · Site details revised at 26 of 26 sitesv5 Show 2 more changesShow less
    • Primary completion date: Sep 2026 to Apr 2026
    • Site details revised at 26 of 26 sites
  3. Study sites: 22 to 26v4
  4. Study sites: 16 to 22v3
  5. Study sites: 5 to 16 Start date changed from estimate of Aug 2025 to Jul 18, 2025v2 Show 1 more changeShow less
    • Start date changed from estimate of Aug 2025 to Jul 18, 2025
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Trial Details
NCT Number NCT07090330
Lead Sponsor Oruka Therapeutics, Inc.
Conditions Plaque Psoriasis
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov